Dilated cardiomyopathy

Is your pooch better or worse off on a cereal-free diet?

Retrieved on: 
Thursday, October 26, 2023

If there’s one issue that has gripped the dog-loving community for the past few years, it’s that of cereals in dog food, and in particular in the ingredients that make up kibbles.

Key Points: 
  • If there’s one issue that has gripped the dog-loving community for the past few years, it’s that of cereals in dog food, and in particular in the ingredients that make up kibbles.
  • The charges are manifold: the grains are said to cause bloating, obesity, gluten intolerance diabetes, and be riddled with mycotoxins (toxins produced by microscopic fungi).

Presumed culprits: cereals!

  • A cereal is a herbaceous plant cultivated mainly for the nutritional value of its grains.
  • Gluten refers to a group of proteins contained in the seeds of cereals from the Poaceae group.

Charge No. 1: Failing to respect a dog’s “natural” diet

  • The first charge levelled against foods containing cereals is that they do not respect the dog’s “natural” diet.
  • The diet of feral dogs, on the other hand, is also mainly based on human waste, made up mostly of cereals and human faeces.

Charge No. 2: Dogs can’t digest starch

  • Contrary to popular belief, dogs have acquired some salivary alpha amylase – an enzyme responsible for kick-starting the process of breaking down starch – throughout their evolution, and can therefore digest a moderate quantity of starch.
  • While dogs can survive without starch in their diets, its presence remains necessary in certain physiological conditions such as gestation and lactation.

Charge No. 3: Gluten makes dogs ill

  • In dogs, the relationship between gluten and intestinal disease has been studied in the Irish setter for around 20 years, with researchers having yet to establish any causality.
  • At present, these are the only two reports of pathologies that could be associated with the presence of gluten.

Charge No. 4: Cereals can poison dogs with mycotoxins

  • They can be present in various plant organs, including grains, fruit and tubers.
  • In humans and animals, mycotoxins can cause various health problems (liver toxicity, kidney toxicity, etc.).
  • Compared with “premium” dog food, the total aflatoxin content is generally higher for “economy” dog food.

So, are cereal-free foods healthier?

  • Finally, recent research has picked upon cases of heart disease (dilated cardiomyopathy) in dogs eating cereal-free foods rich in legumes, including in breeds not predisposed to this pathology.
  • Although the association between cereal-free foods and dilated cardiomyopathy is not yet clear, caution is called for, particularly in the case of pea-based foods.

Verdict: It’s complicated

  • Having eaten cereals since they were domesticated tens of thousands of years ago, dogs have developed the enzymes necessary for them to digest starch.
  • In sum, there is currently no scientific justification for choosing a grain-free food for healthy dogs with no known medical conditions.


The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Veterinarians, Veterinary Cardiologists and Animal Nutritionists Found Grain-Free Diets Had No Negative Impact on Heart Health of Dogs and Did Not Lead to DCM

Retrieved on: 
Tuesday, October 10, 2023

The research appeared in a peer-reviewed article in Frontiers in Animal Science .

Key Points: 
  • The research appeared in a peer-reviewed article in Frontiers in Animal Science .
  • "To identify any changes in cardiac function over time, our multi-disciplinary team collected and examined a wide cross-section of data."
  • Two diets were grain-free, contained pulse ingredients (peas and lentils) and potatoes, and included either low or high amounts of animal protein.
  • Two diets were grain-inclusive, contained no pulse ingredients or potatoes, and included either low or high amounts of animal protein.

BioAro Unveils Its Targeted Cardiac Panel for Patients Facing the Risk of Heart Failure During the Peak of Heart Month

Retrieved on: 
Monday, February 20, 2023

Calgary, Alberta--(Newsfile Corp. - February 20, 2023) - Canada-based biotechnology company BioAro announces the unveiling of its new targeted cardiac panel for patients who face the potential risks of heart failure.

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 20, 2023) - Canada-based biotechnology company BioAro announces the unveiling of its new targeted cardiac panel for patients who face the potential risks of heart failure.
  • Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 Canadians get diagnosed with a new diagnosis of heart failure every year.
  • The launch also seeks to raise awareness of various heart diseases, as part of international heart month in February 2023.
  • BioAro promotes this month to take extra care of heart health and help reduce the mortality rate due to heart diseases.

BioAro is the first Canadian company to launch comprehensive genetic testing panels for various heart diseases

Retrieved on: 
Thursday, February 9, 2023

Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 new Canadians are diagnosed with heart failure every year.

Key Points: 
  • Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 new Canadians are diagnosed with heart failure every year.
  • February is known as International Heart month in order to raise awareness about the various heart conditions and create ways to help in reducing the mortality rate caused due to heart diseases.
  • BioAro is taking an initiative to launch the genetic testing of targeted panels for heart disease conditions using high-throughput next generation sequencing technique.
  • Heart Failure: Heart failure is a chronic, progressive condition in which your heart muscle can't pump enough blood to meet your body's needs all the time.

ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

Retrieved on: 
Tuesday, October 4, 2022

The clinical study was part of the ChromaDex External Research Program (CERP) and investigated the safety and tolerability of the companys proprietary Niagen ingredient, patented nicotinamide riboside or NR, in Stage C heart failure patients with reduced ejection fraction (HFrEF), which occurs when the left ventricular ejection fraction (LVEF) is 40% or less.

Key Points: 
  • The clinical study was part of the ChromaDex External Research Program (CERP) and investigated the safety and tolerability of the companys proprietary Niagen ingredient, patented nicotinamide riboside or NR, in Stage C heart failure patients with reduced ejection fraction (HFrEF), which occurs when the left ventricular ejection fraction (LVEF) is 40% or less.
  • Heart failure is a clinical condition that is caused by structural and functional defects in the heart, which results in impaired filling or pumping of blood.
  • It offers a new therapeutic opportunity in heart failure and other conditions associated with chronic inflammation, said Dr. Rong Tian.
  • This randomized, double-blinded, placebo-controlled clinical study analyzed 30 Stage C heart failure patients over 12 weeks.

Dilated Cardiomyopathy Drugs in Development, 2022 Market Research Report: Market Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022

The "Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders

Retrieved on: 
Monday, February 28, 2022

We look forward to working with these organizations to engage in these efforts as our relationships grow.

Key Points: 
  • We look forward to working with these organizations to engage in these efforts as our relationships grow.
  • Renovacors first target is a rare, monogenic cardiomyopathy associated with mutations in the BAG3 gene.
  • To learn more about how you can support those living with genetic heart disorders and other rare diseases, visit dcmfoundation.org , hfsa.org , aahfn.org and rarediseaseday.org .
  • The companys lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

Allelica, the Leader in Polygenic Risk Scoring, Expands Scientific Advisory Board

Retrieved on: 
Thursday, February 3, 2022

"We are delighted to welcome four leading scientists in their respective fields to help guide Allelica in our mission to advance disease prevention through broader application of polygenic risk scores in healthcare."

Key Points: 
  • "We are delighted to welcome four leading scientists in their respective fields to help guide Allelica in our mission to advance disease prevention through broader application of polygenic risk scores in healthcare."
  • She is an associate professor of medicine and genetics and board certified in internal medicine and medical genetics.
  • In addition to these US-based experts, Allelica's international Advisory Board includes PRS pioneer,Professor Bjarni Vilhjlmsson,from Denmark.
  • Allelica is a leading genomic software company specializing in secure and scalable solutions to implement clinical grade polygenic risk scores (PRSs).

World-Renowned Heart Failure Physicians To Feature Innovative Heart Failure Therapies at Technology and Heart Failure Therapeutics, February 1-2, 2022

Retrieved on: 
Friday, January 28, 2022

is a privately held medical device company headquartered in San Ramon, California.

Key Points: 
  • is a privately held medical device company headquartered in San Ramon, California.
  • The Companys mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy.
  • BioVentrixs Revivent TC system received the CE Mark and is currently pending FDA approval in the United States.
  • When cardiomyopathy occurs, the normal muscle in the heart can thicken, stiffen, thin out, or fill with substances the body produces that do not belong in the heart.

BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.

Retrieved on: 
Thursday, January 27, 2022

This is an exciting time for BioVentrix as we build a platform of synergistic therapies to treat a dilated left ventricle, the root cause of ischemic and idiopathic heart failure, said Jim Dillon, President and CEO, BioVentrix.

Key Points: 
  • This is an exciting time for BioVentrix as we build a platform of synergistic therapies to treat a dilated left ventricle, the root cause of ischemic and idiopathic heart failure, said Jim Dillon, President and CEO, BioVentrix.
  • Professor Andrew Coats, a world-renowned heart failure cardiologist, is joining the board to help guide the company to even greater growth within the heart failure market.
  • MateraCor, Inc. is a Southern California based start-up developing novel approaches to prevent progression and reverse heart failure.
  • The Companys mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy.